US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma ...

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.

A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times ...

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...

Morningstar brands and products Company Portfolio ...

The acquisition also advances Lantheus' capabilities with the addition of Evergreen's radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. "Today marks a ...